Immunotherapy combo aims to beat back recurrent nasopharyngeal cancer
NCT ID NCT05340491
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial tests whether adding an immunotherapy drug called toripalimab to standard chemoradiotherapy helps people with recurrent nasopharyngeal carcinoma live longer. About 212 participants whose cancer has returned after prior treatment and who cannot have surgery will be randomly assigned to receive either chemoradiotherapy alone or chemoradiotherapy plus toripalimab. The study is currently recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Toripalimab (an immunotherapy drug) combined with chemotherapy (gemcitabine and cisplatin) and radiation therapy
What this could lead to
If successful, this combination could improve survival and control of recurrent nasopharyngeal cancer, offering a new treatment option for patients who cannot have surgery.
What could go wrong
This is a phase 3 trial, but results are not yet available. Immunotherapy can cause immune-related side effects, and the added benefit over standard chemoradiotherapy is not guaranteed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
NOT_YET_RECRUITINGShanghai, China
Contact
-
Fujian Province Cancer Hospital
NOT_YET_RECRUITINGFuzhou, China
Contact
-
Guizhou Cancer Hospital
NOT_YET_RECRUITINGGuiyang, China
Contact
-
Jiangxi Cancer Hospital
RECRUITINGNanchang, China
Contact
-
Peking University Third Hospital
RECRUITINGBeijing, China
Contact
-
Sichuan Cancer Hospital
NOT_YET_RECRUITINGChengdu, China
Contact
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510060, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of Guangxi Medical University
RECRUITINGNanning, China
Contact
-
The First Affiliated Hospital of Xiamen University
NOT_YET_RECRUITINGXiamen, China
Contact
-
Xijing Hospital
RECRUITINGXi'an, China
Contact
-
Zhejiang Cancer Hospital
RECRUITINGHangzhou, China
Contact
-
Zhongnan Hospital of Wuhan University
RECRUITINGWuhan, China
Contact